Basic fibroblast growth factor is beneficial for postoperative color uniformity in split-thickness skin grafting.
Color changes of visible and exposed body surfaces, such as the face and extremities, after burn injury or surgery, such as skin grafting, flap, or sclerotherapy for vascular malformations, are sometimes a concern. The consequences reduce the satisfaction of both patients and physicians. An easy and reproducible method has not yet been established for an objective analysis of color changes; therefore, we tested a hand-held color analyzer (NF-333; Nippon Denshoku Co. Ltd) with data transport to a computer database and analysis software for posttreatment skin color change. The parameters included L, a, and b, which measure clarity, red, and yellow, respectively. Two groups were prospectively divided with 20 (11 females and nine males) patients per group. One group received skin grafting plus basic fibroblast growth factor (bFGF) spray daily and the other group received only skin grafting. The patients were randomized by the date of their first visit to our hospital. Patients were treated with bFGF on odd days, while patients who came on even days were included in the non-bFGF-treated group. The donor site for skin grafting was the lateral thighs and the thickness was similar in both groups. The results were compared at 1-year posttreatment follow-up. Clinical and objective assessments of the scars were performed 1 to years after complete healing. Color change differentials in comparison with the surrounding skin were lower with bFGF treatment in all parameters (p<0.01), along with clinical assessment with the Vancouver Scar Scale; therefore, the treatment contribute to a better color match with skin grafting postoperatively.
Akita
Sadanori
S
Graduate School of Biomedical and Sciences, Department of Developmental and Reconstructive Medicine, Division of Plastic and Reconstructive Surgery, Nagasaki University, Nagasaki, Japan. akitas@hf.rim.or.jp
Akino
Kozo
K
Yakabe
Aya
A
Tanaka
Katsumi
K
Anraku
Kuniaki
K
Yano
Hiroki
H
Hirano
Akiyoshi
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002921:Cicatrix / Q000628:therapy; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011182:Postoperative Care; D011446:Prospective Studies; D012880:Skin Pigmentation / Q000187:drug effects*; D013524:Surgical Flaps; D014945:Wound Healing; D055815:Young Adult
D016222:Fibroblast Growth Factor 2